CHE

Rating neutralAI Memo

Chemed

As of 2026-05-30/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-30 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Q1 results and guidance reset • 2026-04-23

Expected move: -9%

Biggest risk

Roto-Rooter margins can stay pressured by paid marketing and weather disruptions, while any VITAS reimbursement or census disappointment would compress the revised guide.

Invalidation

Break below $360 or thesis failure.

What would change my mind?

VITAS is reaccelerating, Medicare Cap pressure is easing, and capital return plus tuck-in acquisitions should support EPS growth faster than revenue growth.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-05-30

Base target

$443

p=50%

Bull target

$510

p=25%

Bear target

$360

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Say-on-pay failed at the annual meeting
VITAS growth stays the main earnings driver
Roto-Rooter weakness is offset by tuck-ins

BearKey bullets

Roto-Rooter revenue and adjusted EBITDA declined in Q1, and elevated marketing expense could persist if lead mix keeps skewing toward paid internet channels.
Share repurchases and franchise acquisitions raise capital-allocation sensitivity if operating trends soften.
The 2026 outlook is more dependent on hospice strength than plumbing recovery, leaving the thesis vulnerable to a segment reversal.

WatchKey bullets

Q1 results and guidance reset

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $443 (p=50%)

Bull/Bear spread: +4% / -26%

Vs latest close: Bull +4% · Base -9% · Bear -26%

Scenario probabilities

Bull Target: $510 (p=25%)Base Target: $443 (p=50%)Bear Target: $360 (p=25%)

Commentary

Primary-source coverage is solid (Q1 release, 10-Q, and annual-meeting 8-K), but external analyst revision/target coverage in the packet is thin and no social context is available. The stock looks roughly fairly valued near the 443 median target, so this is a cautious monitoring view rather than a high-conviction rerating story.

As of 2026-05-30 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

VITAS is reaccelerating, Medicare Cap pressure is easing, and capital return plus tuck-in acquisitions should support EPS growth faster than revenue growth.

Bear Case

Roto-Rooter margins can stay pressured by paid marketing and weather disruptions, while any VITAS reimbursement or census disappointment would compress the revised guide.

Drivers

Scannable catalysts and supporting factors

Say-on-pay failed at the annual meeting
VITAS growth stays the main earnings driver
Roto-Rooter weakness is offset by tuck-ins

Scenarios

Bull Target (Scenario probability)

$510 / p=25% prob

Base Target (Scenario probability)

$443 / p=50% prob

Bear Target (Scenario probability)

$360 / p=25% prob

Price $489 as of 2026-07-10

Nearest Scenario: Bull (∆ 4%)

Targets vs latest close: Bull +4% · Base -9% · Bear -26%

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-04-23
Q1 results and guidance reset
Chemed reported Q1 2026 revenue of $657.5M and adjusted diluted EPS of $5.65, then raised full-year 2026 EPS guidance to $24.00-$24.75 on stronger VITAS performance and higher share repurchase activity. [#IR-2026-04-23]
Prob 80.00% • Move 4.00% • Priced-in 65.00%

Short-term Catalysts

Next few weeks

Say-on-pay failed at the annual meeting
2026-05-19
At the May 18 annual meeting, the non-binding executive compensation proposal failed, with more votes against than for, creating a small governance overhang rather than a core thesis driver. [#8-K-2026-05-19]
Prob 30% • Move -1% • Priced-in 70%

Long-term Catalysts

Months to a year

VITAS growth stays the main earnings driver
2026-12-31
VITAS admissions rose 6.9%, no Florida Medicare Cap billing limitation is anticipated for 2026, and management lifted 2026 ADC, revenue, and EBITDA-margin guidance after quicker-than-expected normalization. [#IR-2026-04-23][#10-Q-2026-04-28]
Prob 65% • Move 3% • Priced-in 55%
Roto-Rooter weakness is offset by tuck-ins
2026-12-31
Roto-Rooter revenue fell 0.9% and adjusted EBITDA fell 9.6% in Q1, but two franchise acquisitions should add $5.0M-$5.5M of 2026 revenue and support the roll-up strategy. [#IR-2026-04-23]
Prob 55% • Move 2% • Priced-in 45%

Risks

Roto-Rooter revenue and adjusted EBITDA declined in Q1, and elevated marketing expense could persist if lead mix keeps skewing toward paid internet channels.
Share repurchases and franchise acquisitions raise capital-allocation sensitivity if operating trends soften.
The 2026 outlook is more dependent on hospice strength than plumbing recovery, leaving the thesis vulnerable to a segment reversal.
VITAS remains exposed to Medicare Cap, reimbursement, patient-mix, and census volatility even after the Q1 improvement.

Peers

Symbol	Summary
ABT	Large diversified medtech and diagnostics peer; useful valuation anchor, but much broader and less operationally similar to Chemed's hospice/plumbing mix.
BSX	Procedure-growth medtech with strong execution and hospital exposure; a better quality-growth comp, though still far larger than CHE.
EW	Premium structural-heart franchise with a high multiple; helpful for medtech sentiment, but less relevant to Chemed's end-market profile.
GKOS	Smaller ophthalmic device name with higher growth and volatility; closer on mid-cap market-cap profile than on business mix.
BLCO	Eye-care/vision-care company with a similar market-cap band; a looser but still relevant healthcare equipment and services peer.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-05-30

AI Stock Memo: CHE - Chemed - RankAlpha